Q-omics provides the consensus-scored MYB profile across patient tissues and cancer cell-line models. MYB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MYB is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, MYB RNA expression shows 18,892 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, BLCA, and TGCT as cancer lineages where MYB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYB survival associations across molecular data types. MYB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYB RNA expression–survival associations across cancer types. High MYB expression shows unfavorable associations in MESO, ACC, UVM and KIRP, but favorable associations in HNSC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MYB RNA expression.
This table summarizes MYB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYB shows lower tumor expression in HNSC and higher tumor expression in BLCA, STAD, BRCA, KIRP and KIRC. The BLCA box plot shows higher MYB RNA expression in tumor versus normal tissue (log2 FC = +1.451, t-test p < 0.001).
This table shows molecular features associated with MYB in patient tissues and cancer cell lines. In patient samples, MYB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
